White-matter connectivity related to paliperidone treatment response in patients with schizophrenia

被引:10
作者
Kim, Min-Kyoung [1 ]
Kim, Borah [1 ]
Lee, Kang Soo [1 ]
Kim, Chan Mo [2 ]
Bang, Seong Yun [3 ]
Choi, Tai Kiu [1 ]
Lee, Sang-Hyuk [1 ]
机构
[1] CHA Univ, CHA Bundang Med Ctr, Dept Psychiat, Songnam, South Korea
[2] Kwangwoon Univ, Dept Business Adm, Seoul, South Korea
[3] CHA Univ, Grad Sch Hlth & Welf, Dept Publ Hlth, Songnam, South Korea
关键词
Schizophrenia; paliperidone; treatment response; white-matter connectivity; neuroimaging; PREDICTS TREATMENT RESPONSE; 1ST-EPISODE SCHIZOPHRENIA; EXTENDED-RELEASE; ATYPICAL ANTIPSYCHOTICS; NEGATIVE SYMPTOMS; ABNORMALITIES; DYSFUNCTION; MEDICATION; ANISOTROPY; REMISSION;
D O I
10.1177/0269881115625114
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this study was to examine whether white-matter (WM) connectivity of patients with schizophrenia at early stage of treatment is related to treatment response after paliperidone extended-release (ER) treatment. Forty-one patients with schizophrenia and 17 age- and sex-matched healthy control subjects were included in this study. Brain magnetic resonance scans at 3 Tesla were conducted at early stage of treatment. Voxel-wise statistical analysis of the fractional anisotropy (FA) data was performed using Tract-Based Spatial Statistics. At baseline and eight weeks after paliperidone treatment, patients were assessed using the Positive and Negative Syndrome Scale, the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms. Among the patients with schizophrenia, the FA values of the corpus callosum, corona radiata, internal capsule, external capsule, superior longitudinal fasciculus and fronto-temporal WM regions showed significant negative correlations with scores of the treatment response. The current study suggests that the treatment response after paliperidone ER treatment may be associated with the fronto-temporo-limbic WM connectivity at early stage of treatment in patients with schizophrenia, and it could be used as a predictor of treatment response to paliperidone ER treatment after studies with large samples verify these results.
引用
收藏
页码:294 / 302
页数:9
相关论文
共 49 条
  • [1] Remission in schizophrenia: Proposed criteria and rationale for consensus
    Andreasen, NC
    Carpenter, WT
    Kane, JM
    Lasser, RA
    Marder, SR
    Weinberger, DR
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) : 441 - 449
  • [2] ANDREASEN NC, 1989, BRITISH JOURNAL OF PSYCHIATRY, VOL 155, SUPP NO. 7, P49
  • [3] Andreasen NC, 1984, SCALE ASSESSMENT U I
  • [4] Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia
    Bartzokis, George
    Lu, Po H.
    Nuechterlein, Keith H.
    Gitlin, Michael
    Doi, Clarissa
    Edwards, Nancy
    Lieu, Christopher
    Altshuler, Lori L.
    Mintz, Jim
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) : 13 - 22
  • [5] Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
    Bartzokis, George
    [J]. NEUROPHARMACOLOGY, 2012, 62 (07) : 2137 - 2153
  • [6] Bridler R, 2003, SWISS MED WKLY, V133, P63
  • [7] Altered Functional and Anatomical Connectivity in Schizophrenia
    Camchong, Jazmin
    MacDonald, Angus W., III
    Bell, Christopher
    Mueller, Bryon A.
    Lim, Kelvin O.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 (03) : 640 - 650
  • [8] A selective review of structural connectivity abnormalities of schizophrenic patients at different stages of the disease
    Canu, Elisa
    Agosta, Federica
    Filippi, Massimo
    [J]. SCHIZOPHRENIA RESEARCH, 2015, 161 (01) : 19 - 28
  • [9] Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms
    Canuso, C. M.
    Bossie, C. A.
    Turkoz, I.
    Alphs, L.
    [J]. SCHIZOPHRENIA RESEARCH, 2009, 113 (01) : 56 - 64
  • [10] RISPERIDONE IN THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - A METAANALYSIS
    CARMAN, J
    PEUSKENS, J
    VANGENEUGDEN, A
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (04) : 207 - 213